RA
CPRX

Royce & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

Royce & Associates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
358,642
-1,731,264
-83% -$51.1M 0.09% 351
2026
Q1 		$51.7M Buy
2,089,906
+179,139
+9% +$4.27M 0.51% 33
2025
Q4 		$44.6M Sell
1,910,767
-124,198
-6% -$2.77M 0.45% 41
2025
Q3 		$40.1M Buy
2,034,965
+452,103
+29% +$9.3M 0.4% 60
2025
Q2 		$34.3M Sell
1,582,862
-15,498
-1% -$366K 0.35% 73
2025
Q1 		$38.8M Sell
1,598,360
-265,991
-14% -$5.99M 0.42% 58
2024
Q4 		$38.9M Sell
1,864,351
-156,754
-8% -$3.37M 0.36% 65
2024
Q3 		$40.2M Sell
2,021,105
-140,917
-7% -$2.61M 0.37% 74
2024
Q2 		$33.5M Buy
2,162,022
+78,009
+4% +$1.21M 0.31% 85
2024
Q1 		$33.2M Buy
2,084,013
+340,939
+20% +$5.14M 0.3% 95
2023
Q4 		$29.3M Buy
1,743,074
+131,372
+8% +$1.8M 0.27% 98
2023
Q3 		$18.8M Buy
1,611,702
+571,714
+55% +$7.65M 0.19% 149
2023
Q2 		$14M Buy
1,039,988
+424,020
+69% +$6.1M 0.14% 209
2023
Q1 		$10.2M Buy
615,968
+84,079
+16% +$1.39M 0.1% 303
2022
Q4 		$9.89M Sell
531,889
-126,658
-19% -$1.95M 0.1% 295
2022
Q3 		$8.45M Sell
658,547
-1,441,678
-69% -$17.1M 0.1% 309
2022
Q2 		$14.7M Sell
2,100,225
-161,682
-7% -$1.19M 0.15% 186
2022
Q1 		$18.8M Sell
2,261,907
-321,961
-12% -$2.28M 0.16% 174
2021
Q4 		$17.5M Sell
2,583,868
-423,126
-14% -$2.78M 0.13% 236
2021
Q3 		$15.9M Sell
3,006,994
-66,852
-2% -$366K 0.12% 275
2021
Q2 		$17.7M Sell
3,073,846
-175,804
-5% -$907K 0.12% 283
2021
Q1 		$15M Buy
3,249,650
+844,521
+35% +$3.36M 0.1% 328
2020
Q4 		$8.03M Buy
2,405,129
+620,239
+35% +$2.08M 0.07% 440
2020
Q3 		$5.3M Buy
1,784,890
+474,984
+36% +$1.86M 0.06% 456
2020
Q2 		$6.05M Buy
1,309,906
+665,915
+103% +$2.99M 0.07% 409
2020
Q1 		$2.48M Sell
643,991
-136,791
-18% -$561K 0.03% 543
2019
Q4 		$2.93M Buy
+780,782
New +$3.65M 0.03% 617

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's CPRX Position: Q2 2026 in Review

Royce & Associates reduced its Catalyst Pharmaceutical (CPRX) stake by 83% in Q2 2026, selling an estimated $51.1M and leaving 358,642 shares worth $11.3M. The position accounts for 0.09% of the portfolio, ranked #351.

Royce & Associates first reported a position in CPRX in Q4 2019 and has held it in 27 quarters since. The position peaked at $51.7M in Q1 2026. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Royce & Associates held 358,642 shares of Catalyst Pharmaceutical worth $11.3M as of Q2 2026.
  • Royce & Associates sold 1,731,264 Catalyst Pharmaceutical shares in Q2 2026, an estimated $51.1M.
  • Catalyst Pharmaceutical made up 0.09% of Royce & Associates's portfolio in Q2 2026, its #351 holding.
  • Royce & Associates first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • Royce & Associates's Catalyst Pharmaceutical position peaked at $51.7M in Q1 2026.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.